Library/For Weight Loss/Retatrutide

RUO · Not ApprovedTriple AgonistFor Weight LossPhase 3 Ongoing+2 more★ Popular

Retatrutide

GLP-1 plus GIP plus glucagon. We read all 60 studies. The protocol is below.

Updated 19 May 2026Read 9 minEvidence ●●●○○Citations 60

+ Add to Stack⚖ Compare

⚖ Compare side-by-side ⎙ Print companion card

Free — puts Retatrutide on your decision board.

The Retatrutide Report · $19

Everything you need to start: dose, sourcing, safety, our verdict.

One purchase · yours forever

Built from 60 cited studies.

Status

Research-only

Class

Triple Agonist

Evidence

3/ 5●●●○○

FDA status

$19 ↓

Phase 2 weight loss

$19 ↓

Phase 2 enrollment

$19 ↓

⚠ Heart Rate +7 bpm

Read this if

you've already lost weight on tirzepatide and want to know what the next-bigger-number drug looks like
you're in a retatrutide-specific Discord or r/peptides_GLP1 and want a sober read
you're tracking Lilly's TRIUMPH phase 3 timeline

Skip this if

you have a personal or family history of medullary thyroid carcinoma
you have arrhythmia, uncontrolled hypertension, or significant cardiovascular disease — the heart-rate increase is real
you want an approved drug — this isn't one yet

The 4 ways you can buy Retatrutide

No FDA-approved retatrutide exists yet.

Compounded 503A

⚠

Not on the FDA bulks list

$200–$600/mo

Legally contested — the pharmacies selling it are under FDA pressure.

RUO (research-only)

✓

Sold 'for research only'

$120–$280/mo

The dominant supply; the triple agonist is hard to synthesize cleanly, sub-95% purity is common.

Gray market

✓

Unregulated overseas import

$10–$70/mo

Growing as compounders exit; identity failures (powder is actually tirzepatide) are documented.

Click any lane for the full Sourcing breakdown. Prices and lane availability vary by molecule — this is the per-peptide snapshot, not a generic table.

First 90 days · Retatrutide

What we'd actually do

Weeks 1–2

GI side effects start. Nausea is the rate-limiter. Don't titrate up if you can't tolerate the starting dose — the side-effect curve gets steeper, not flatter.

Weeks 4–8

Appetite suppression becomes the obvious effect. 1–2 lbs/week is typical. Hit a plateau? Hold the dose, don't immediately bump.

Week 12 — decide

Bloodwork: A1c, lipids, liver enzymes, fasting insulin. Visible weight change should be 5–10%. If the trajectory is flat at 12 weeks and you've titrated, this isn't your molecule.

Quit if

Pancreatitis-like pain (severe upper-abdominal, won't sit still): stop and call your doctor.
Gallbladder pain or persistent vomiting that won't resolve.
Severe muscle loss without resistance training (the 'GLP-1 face' is real — protein floor matters).
12 weeks at full dose with zero weight movement (rare, but real).

Identity

What it is.

Retatrutide is Eli Lilly's follow-up to tirzepatide. It's a synthetic that hits three gut and metabolic hormone receptors at once: GLP-1, GIP, and glucagon. The industry nickname is the "triple agonist."

The glucagon arm is the new piece. On its own, glucagon raises blood sugar — which sounds like the wrong direction for a diabetes drug. But it also increases energy expenditure and pushes the liver to burn fat. Paired with the /GIP appetite suppression, the net effect in early trials has been more weight loss than tirzepatide produced.

As of mid-2026 it is not yet FDA approved — phase 3 trials (TRIUMPH program) are still running. versions exist; we cover the legal framework in our methodology.

TL;DR

TL;DR. 30-second version.

The compressed verdict — what Retatrutide actually is, what the human evidence shows, and the watch-for in three bullets. Locked.

Get the report · $19 ↓

Mechanism

Mechanism.

Mechanism · in the Retatrutide report

How the molecule actually works — receptor profile, downstream signaling, what to expect mechanistically.

Get the report · $19 ↓

Evidence

Evidence. What we actually know in humans.

Evidence · in the Retatrutide report

The trial breakdown — phase, n, primary endpoint, who funded, what hit, what didn't.

Get the report · $19 ↓

Human-Evidence Factbox

FDA status

Phase 2 weight loss

Phase 2 enrollment

Receptors hit

Expected approval window

$19 ↓

Resting heart rate change

$19 ↓

Only realistic form

$19 ↓

Identity-failure risk

$19 ↓

Dose

Dose. The actual protocol.

Dose · in the Retatrutide report

The specific protocol — dose, titration schedule, cycle pattern, frequency, route.

We read 60 studies to write this report.

Get the report · $19 ↓

Sourcing

Sourcing. Where the cohort actually buys.

Sourcing · in the Retatrutide report

Sourcing breakdown — vendor methodology, red flags, our published test results, COA checklist.

We read 60 studies to write this report.

Get the report · $19 ↓

Safety

Safety. Side effects.

Safety · in the Retatrutide report

The watch-for list — contraindications, drug interactions, monitoring labs, when to stop.

Get the report · $19 ↓

Editorial Position

Editorial position.

Editorial Position · in the Retatrutide report

Our editorial position — explicit yes / no / depends, with the reasoning behind it.

Get the report · $19 ↓

Citations

Citations.

+Show all 60 citations

The Retatrutide Report · $19

Everything you need to start.

Dose, sourcing, safety, our verdict. One purchase. Yours forever.

Built from 60 cited studies.

Or get every report. All reports — $99 once · Pro — $29/mo.

Compare tiers →